To mitigate the risk of hypoglycaemia, we sought to improve GK activity by blocking GKRP. In this article we explain the identification of two powerful tiny-molecule GK–GKRP disruptors (AMG-1694 and AMG-3969) that normalized blood glucose stages in various rodent models of diabetic issues. These compounds potently reversed the inhibitory imp… Read More